The Patent Finder

Treatment of Inflammatory Diseases Using Placental Stem Cells

Celeniv Pte. Ltd.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application 12/030,161, filed Feb 12, 2008. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 8,916,146Treatment of Inflammatory Diseases Using Placental Stem Cells
In force
 · High confidence
Celeniv Pte. Ltd.In force
High confidence
US 11,723,930Treatment of Inflammatory Diseases Using Placental Stem Cells
In force
 · High confidence
Celeniv Pte. Ltd.In force
High confidence
US 8,460,650Treatment of Inflammatory Diseases Using Placental Stem Cells
Lapsed Jun 11, 2025 on the fee record
Ended Jun 11, 2025 · High confidence
Celeniv Pte. Ltd.Lapsed Jun 11, 2025 on the fee recordEnded Jun 11, 2025
High confidence
US 8,753,883Treatment of Psoriasis Using Placental Stem Cells
Lapsed Jun 17, 2026 on the fee record
Ended Jun 17, 2026 · High confidence
Celeniv Pte. Ltd.Lapsed Jun 17, 2026 on the fee recordEnded Jun 17, 2026
High confidence
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Celeniv Pte. Ltd..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited